SCHEDULE: Vanguard Divests REGENXBIO Stake Amid Internal Realignment

The Vanguard Group reports 0% beneficial ownership in REGENXBIO Inc. following an internal realignment that disaggregated reporting responsibilities to its subsidiaries.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 10 to Schedule 13G for REGENXBIO Inc. Common Stock.
• As of the event date of March 13, 2026, The Vanguard Group, Inc. reports 0% beneficial ownership of REGENXBIO Inc. Common Stock.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries and business divisions of The Vanguard Group, Inc. will now report their beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. itself no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
• The filing certifies that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of REGENXBIO Inc.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative development for REGENXBIO Inc. as a major institutional investor has formally reported zero beneficial ownership, even if due to internal restructuring, which could impact investor perception and potentially lead to selling pressure.

Positives

• The reporting person, The Vanguard Group, certifies that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of REGENXBIO Inc., indicating no activist intent.

Negatives

• The Vanguard Group, a prominent institutional investor, now reports 0% beneficial ownership in REGENXBIO Inc., indicating a complete divestment of the reported stake by the parent entity.
• This change, while explained by internal restructuring, removes a major institutional name from the direct beneficial ownership list for REGENXBIO Inc.

Risks

• The disaggregation of beneficial ownership reporting to subsidiaries means that The Vanguard Group, Inc. itself no longer directly reports holdings, which could be misinterpreted by some investors as a complete institutional exit if the context of the internal realignment is not fully understood.

Future Outlook

The filing primarily addresses a change in The Vanguard Group's internal reporting structure for beneficial ownership, rather than providing a future outlook for REGENXBIO Inc. The implication is that Vanguard's subsidiaries will continue to manage and report their holdings separately.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment."
• "In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."
• "I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that large institutional investors like The Vanguard Group frequently adjust their internal reporting structures, which can lead to changes in their reported beneficial ownership without necessarily reflecting a change in their overall investment strategy or conviction in the underlying company. This disaggregation is a compliance-driven event for Vanguard, aligning with SEC guidance.

Corporate Governance

Stakeholder Impact

• Shareholders: May perceive the 0% reported ownership by The Vanguard Group as a negative signal, potentially leading to selling pressure, despite the internal realignment explanation.
• Investment Professionals: Will need to track individual Vanguard subsidiaries' filings to understand the full extent of Vanguard's aggregate holdings in REGENXBIO Inc.

Next Steps

• Vanguard's subsidiaries or business divisions will now report their beneficial ownership of REGENXBIO Inc. separately in future filings.

Key Dates

Recommendation

The filing indicates that The Vanguard Group, a significant institutional investor, no longer holds any beneficial ownership in REGENXBIO Inc. While attributed to an internal realignment, this formal divestment by the parent entity could signal a lack of conviction or a strategic shift away from the stock by this specific reporting entity. This could lead to negative market sentiment and potential selling pressure, making a 'sell' recommendation prudent for investors who prioritize institutional backing.

Keywords

REGENXBIO, Vanguard Group, Schedule 13G, beneficial ownership, common stock, institutional ownership, SEC filing, investment adviser, internal realignment